Stock Price Forecast
The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +262.32% increase from the last price of 2.07.
Similarly, Is BNGO good stock?
Based on his analysis, DeGeeter rates BNGO stock as « outperform » with a $14 value. Other analysts are also bullish on the company. Those tracked by the Wall Street Journal have BNGO rated as a consensus « buy » with an average $12 price target.
Is BNGO buy or sell? Bionano Genomics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Thereof, Is BNGO a strong buy?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Bionano Genomics stock is Buy based on the current 3 buy ratings for BNGO.
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.
Who owns Bionano genomics?
Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
Is BNGO a meme stock?
Admittedly, it has been a while since Bionano Genomics (NASDAQ:BNGO) stock has been a “hot stock,” a “meme stock” or whatever you want to call it. Since its big drop in late February and early March, the market has had mixed feelings about this life sciences company.
Will BNGO get FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
Does Ark invest in BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Is BNGO an American company?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. … The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
How many shares are there of BNGO?
BioNano Genomics Inc (US:BNGO) has 292 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 83,218,166 shares.
What sector is BNGO in?
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space.
What institutions are buying BNGO?
Bionano Genomics (NASDAQ:BNGO) Institutional Buying and Selling
| Reporting Date | Hedge Fund | Ownership in Company |
|---|---|---|
| 2/14/2022 | Nuveen Asset Management LLC | 0.357% |
| 2/14/2022 | Barclays PLC | 0.123% |
| 2/14/2022 | GSA Capital Partners LLP | 0.019% |
| 2/14/2022 | Mutual Advisors LLC | 0.017% |
What does Bionano genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
Why does Bionano have tremendous potential?
The Bottom Line on BNGO Stock
Saphyr allows diseases to be more effectively researched than competing products. And, it is tremendously cheaper than other genomic-mapping tools. But it could also more successfully determine patients more susceptible to severe cases of viruses. These viruses include Covid-19.
What is a Bionano chip?
Built using proprietary Nanochannel technology, Bionano Chips for the Saphyr® and Irys® systems linearize DNA, enabling high-speed, high-throughput optical genome mapping and structural variation detection for a variety of applications including human and clinical research.
Is BNGO in ARKG?
Ark Invest’s Chapter in the BNGO Stock Story
The fund manager has sent some public praise BNGO’s way. Ark even has a special portfolio — Ark Genomic Revolution ETF (NYSEARCA:ARKG) — for just that sort of stock material. Thus, it was only a matter of time before the stock caught on, right?
What does BNGO genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations.
How does Bionano genomics make money?
Revenue is produced by either directly selling the data to outsiders or by leveraging it for internal reasons, such as increasing the efficacy of advertising.
Who are Bionano genomics competitors?
13 Competitors
BioNano Genomics’s competitors are BioDiscovery, Fluxion Biosciences, IRX Therapeutics, Hepregen, Genvault Corporation and more.
Who is BNGO stock?
(BNGO) Stock Price, News, Quote & History – Yahoo Finance.
…
Performance Outlook.
| Previous Close | 2.3200 |
|---|---|
| Bid | 2.1800 x 27000 |
| Ask | 2.2300 x 29200 |
| Day’s Range | 2.1800 – 2.3200 |
| 52 Week Range | 1.6200 – 9.1200 |
How much cash does BNGO have?
Bionano Genomics cash on hand from 2017 to 2021.
…
Compare BNGO With Other Stocks.
| Bionano Genomics Annual Cash on Hand (Millions of US $) | |
|---|---|
| 2020 | $38 |
| 2019 | $17 |
| 2018 | $17 |
| 2017 | $1 |
Is BNGO in Russell?
(Nasdaq: BNGO) announced today that it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on Monday, June 28, 2021, as part of the 2021 Russell indexes reconstitution.
What does BNGO company do?
Company Description
The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.
Join TheMoney.co community and don’t forget to share this post !
